Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): A multicentre, phase 2, randomised controlled trial

The Lancet Oncology

Volumn 16, Issue 16, 2015, Pages 1691-1699

  Röllig, Christoph ^a   Serve, Hubert ^b   Hüttmann, Andreas ^c   Noppeney, Richard ^c   Müller Tidow, Carsten ^d,e   Krug, Utz ^e,f   Baldus, Claudia D ^g   Brandts, Christian H ^b   Kunzmann, Volker ^h   Einsele, Hermann ^h   Krämer, Alwin ⁱ   Schäfer Eckart, Kerstin ^j   Neubauer, Andreas ^k   Burchert, Andreas ^k   Giagounidis, Aristoteles ^l   Krause, Stefan W ^m   Mackensen, Andreas ^m   Aulitzky, Walter ⁿ   Herbst, Regina ^o   Hänel, Mathias ^o   Kiani, Alexander ^p   Frickhofen, Norbert ^q   Kullmer, Johannes ^r   Kaiser, Ulrich ^s   Link, Hartmut ^t   Geer, Thomas ^u   Reichle, Albert ^v   Junghanß, Christian ^w   Repp, Roland ^x   Heits, Frank ^y   Dürk, Heinz ^z   Hase, Jana ^a   Klut, Ina Maria ^aa   Illmer, Thomas ^ab   Bornhäuser, Martin ^a   Schaich, Markus ^ac   Parmentier, Stefani ^ac   Görner, Martin ^ad   Thiede, Christian ^a   von Bonin, Malte ^a,ae,af   Schetelig, Johannes ^a,ag   Kramer, Michael ^a   Berdel, Wolfgang E ^e   Ehninger, Gerhard ^a   more..

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d Universitatsklinikum Halle Saale   (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f KLINIKUM LEVERKUSEN   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j KLINIKUM NÜRNBERG   (Germany)

^k UNIVERSITY HOSPITAL MARBURG   (Germany)

^l Hämatologie und Palliativmedizin   (Germany)

^m UNIVERSITY HOSPITAL ERLANGEN   (Germany)

ⁿ ROBERT BOSCH HOSPITAL   (Germany)

^o KLINIKUM CHEMNITZ   (Germany)

^p INSTITUTE OF PATHOLOGY   (Germany)

^q Klinik Innere Medizin III   (Germany)

^r Medizinische Klinik II   (Germany)

^s ST BERNWARD KRANKENHAUS   (Germany)

^t Klinik für Innere Medizin 1   (Germany)

^u Innere Medizin III Kardiologie und Angiologie   (Germany)

^v UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^w ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^x KLINIKUM BAMBERG   (Germany)

^y Agaplesion Diakonieklinikum Rotenburg   (Germany)

^z St Marien Hospital Hamm   (Germany)

^aa UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^ab Gemeinschaftspraxis Hämatologie und Onkologie   (Germany)

^ac Rems Murr Klinikum Winnenden   (Germany)

^ad OWL University   (Germany)

^ae Deutsches Konsortium für Translationale Krebsforschung DKTK   (Germany)

^af GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^ag DKMS Nabelschnurblutbank   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; CYTARABINE; DAUNORUBICIN; PLACEBO; SORAFENIB; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

ACUTE MYELOBLASTIC LEUKEMIA; ADD ON THERAPY; ADULT; AGE DISTRIBUTION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; CYTOGENETIC RISK; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; EPISTAXIS; EVENT FREE SURVIVAL; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENETIC RISK; GERMANY; HAND FOOT SYNDROME; HEADACHE; HEART DISEASE; HUMAN; HYPERTENSION; INFECTION; INTENTION TO TREAT ANALYSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENCE FREE SURVIVAL; SIDE EFFECT; SKIN DISEASE; SURVIVAL RATE; SURVIVAL TIME; VOMITING; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; AGE; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; MORTALITY; NEOADJUVANT THERAPY; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGE FACTORS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CYTARABINE; DAUNORUBICIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; GERMANY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; RECURRENCE; RISK FACTORS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84949484439     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00362-9     Document Type: Article

References (33)

1. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006, 5:835-844.
2. Klein M, Schermuly RT, Ellinghaus P, et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 2008, 118:2081-2090.
3. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006, 98:326-334.
4. Zhang W, Konopleva M, Shi YX, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008, 100:184-198.
5. Zhang W, Konopleva M, Ruvolo VR, et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008, 22:808-818.
6. Cummins KD, Jane SM, Ninkovic S, et al. Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia. Blood Cancer J 2014, 4:e237.
7. Metzelder SK, Schroeder T, Finck A, et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia 2012, 26:2353-2359.
8. Rollig C, Brandts C, Shaid S, et al. Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. Leuk Lymphoma 2012, 53:1062-1067.
9. Fesler MJ, Richart JM, Petruska PJ A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount. Leuk Res 2010, 34:e268-e269.
10. Sharma M, Ravandi F, Bayraktar UD, et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant 2011, 17:1874-1877.
11. Winkler J, Rech D, Kallert S, et al. Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report. Leuk Res 2010, 34:e270-e272.
12. Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009, 113:6567-6571.
13. Macdonald DA, Assouline SE, Brandwein J, et al. A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. Leuk Lymphoma 2013, 54:760-766.
14. Borthakur G, Kantarjian H, Ravandi F, et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 2011, 96:62-68.
15. Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010, 28:1856-1862.
16. Ravandi F, Arana YC, Cortes JE, et al. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia 2014, 28:1543-1545.
17. Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol 2013, 31:3110-3118.
18. Rollig C, Bornhauser M, Thiede C, et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol 2011, 29:2758-2765.
19. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
20. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99:4326-4335.
21. Brookmeyer R, Crowley J A confidence interval for the median survival time. Biometrics 1982, 38:29-41.
22. Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 2013, 121:4655-4662.
23. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1909-1918.
24. Buchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009, 27:61-69.
25. Atallah E, Cortes J, O'Brien S, et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood 2007, 110:3547-3551.
26. Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients. Blood 2008, 111:2527-2537.
27. Ding W, Knox TR, Tschumper RC, et al. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood 2010, 116:2984-2993.
28. Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000, 95:2637-2644.
29. Rollig C, Thiede C, Gramatzki M, et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood 2010, 116:971-978.
30. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999, 94:1086-1099.
31. Thol F, Damm F, Ludeking A, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011, 29:2889-2896.
32. Ferrara F, Criscuolo C, Riccardi C, et al. FLT3 mutations have no prognostic impact in elderly patients with acute myeloid leukemia and normal karyotype. Am J Hematol 2009, 84:532-535.
33. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002, 100:4372-4380.